Table 1. Demographics and clinical characteristics among neuroendocrine tumors.
| Characteristic | Colon (N=7,967) | Rectum (N=11,929) |
|---|---|---|
| Age at diagnosis | ||
| N | 7,967 | 11,929 |
| Mean (SD) | 57.0 (16.7) | 55.4 (11.6) |
| Median | 58.0 | 54.0 |
| Q1, Q3 | 47.0, 69.0 | 50.0, 62.0 |
| Range | (18.0–90.0) | (18.0–90.0) |
| Sex | ||
| Male | 3,430 (43.1%) | 5,632 (47.2%) |
| Female | 4,537 (56.9%) | 6,297 (52.8%) |
| Race | ||
| Missing | 86 | 287 |
| White | 6,726 (85.3%) | 7,106 (61.0%) |
| Black | 970 (12.3%) | 3,477 (29.9%) |
| Other | 185 (2.3%) | 1,059 (9.1%) |
| Spanish/Hispanic origin | ||
| Missing | 449 | 799 |
| Non-Hispanic/Non-Spanish | 7,159 (95.2%) | 10,191 (91.6%) |
| Hispanic/Spanish | 359 (4.8%) | 939 (8.4%) |
| Charlson-Deyo Score | ||
| 0 | 6,287 (78.9%) | 10,147 (85.1%) |
| 1 | 1,299 (16.3%) | 1,431 (12.0%) |
| 2+ | 381 (4.8%) | 351 (2.9%) |
| Primary payer | ||
| Missing | 123 | 218 |
| No insured | 324 (4.1%) | 395 (3.4%) |
| Private insurance | 4,241 (54.1%) | 7,657 (65.4%) |
| Medicaid | 483 (6.2%) | 887 (7.6%) |
| Medicare | 2,715 (34.6%) | 2,584 (22.1%) |
| Other government | 81 (1.0%) | 188 (1.6%) |
| Percent no high school degree | ||
| Missing | 77 | 81 |
| 21% or more | 1,143 (14.5%) | 2,401 (20.3%) |
| 13% to 20.9% | 1,961 (24.9%) | 3,128 (26.4%) |
| 7% to 12.9% | 2,680 (34.0%) | 3,577 (30.2%) |
| Less than 7% | 2,106 (26.7%) | 2,742 (23.1%) |
| Median income quartiles | ||
| Missing | 82 | 86 |
| Less than $38,000 | 1,272 (16.1%) | 2,378 (20.1%) |
| $38,000 to $47,999 | 1,691 (21.4%) | 2,547 (21.5%) |
| $48,000 to $62,999 | 2,129 (27.0%) | 3,034 (25.6%) |
| $63,000+ | 2,793 (35.4%) | 3,884 (32.8%) |
| Urban/rural | ||
| Missing | 248 | 380 |
| Metro | 6,664 (86.3%) | 10,425 (90.3%) |
| Urban | 921 (11.9%) | 1,000 (8.7%) |
| Rural | 134 (1.7%) | 124 (1.1%) |
| Year of diagnosis | ||
| N | 7,967 | 11,929 |
| Mean (SD) | 2,009.8 (3.2) | 2,009.5 (3.1) |
| Median | 2,010.0 | 2,010.0 |
| Q1, Q3 | 2,007.0, 2,013.0 | 2,007.0, 2,012.0 |
| Range | (2,004.0–2,014.0) | (2,004.0–2,014.0) |
| Clinical stage | ||
| Missing | 5,201 | 7,318 |
| Stage 0 | 18 (0.7%) | 46 (1.0%) |
| Stage 1 | 923 (33.4%) | 4,106 (89.0%) |
| Stage 2 | 461 (16.7%) | 202 (4.4%) |
| Stage 3 | 514 (18.6%) | 119 (2.6%) |
| Stage 4 | 850 (30.7%) | 138 (3.0%) |
| Clinical T Stage | ||
| Missing | 5,601 | 7,333 |
| T0 | 123 (5.2%) | 59 (1.3%) |
| T1 | 882 (37.3%) | 4,101 (89.2%) |
| T2 | 359 (15.2%) | 236 (5.1%) |
| T3 | 693 (29.3%) | 157 (3.4%) |
| T4 | 309 (13.1%) | 43 (0.9%) |
| Clinical N Stage | ||
| Missing | 3,963 | 5,981 |
| N0 | 3,071 (76.7%) | 5,767 (97.0%) |
| N1 | 743 (18.6%) | 155 (2.6%) |
| N2 | 190 (4.7%) | 26 (0.4%) |
| Clinical M Stage | ||
| Missing | 555 | 719 |
| M0 | 6,555 (88.4%) | 11,069 (98.7%) |
| M1 | 857 (11.6%) | 141 (1.3%) |
| Surgical procedure type | ||
| Local | 525 (6.6%) | 10,624 (89.1%) |
| Radical resection | 7,442 (93.4%) | 1,305 (10.9%) |
| Surgical margins | ||
| Missing | 271 | 2,234 |
| No residual tumor | 6,777 (88.1%) | 8,469 (87.4%) |
| Residual tumor | 919 (11.9%) | 1,226 (12.6%) |
| Number of regional lymph nodes examined | ||
| N | 7,785 | 11,589 |
| Mean (SD) | 13.2 (11.5) | 1.0 (4.8) |
| Median | 13.0 | 0.0 |
| Q1, Q3 | 3.0, 19.0 | 0.0, 0.0 |
| Range | (0.0–90.0) | (0.0–90.0) |
| Number of positive nodes (among those with at least 1 positive node) | ||
| N | 4,123 | 426 |
| Mean (SD) | 5.5 (5.5) | 6.2 (9.4) |
| Median | 4.0 | 3.0 |
| Q1, Q3 | 2.0, 7.0 | 2.0, 7.0 |
| Range | (1.0–78.0) | (1.0–88.0) |